Antibody Information

General Information of This Antibody

Antibody ID	ANI0MZJIG
Antibody Name	OMTX005
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG1-kappa
Antigen Name	Prolyl endopeptidase FAP (FAP)	Antigen Info

The Activity Data of This Antibody

Antibody Activity Information 1					[1]
Half Maximal Effective Concentration (EC50)	76	pM	HT-1080 cells (FAP expression)	CVCL_0317
Antigen Expression	Positive FAP expression (FAP+++/++)
Antibody Function	Confirm the effect of the drug conjugation with the anti-FAP mAb and ADC on binding activity to cell line.
Antibody Antigen Binding Assay	The binding and internalization properties of OMTX705 were compared with naked OMTX005 anti-FAP antibody and an isotype/TAM558 control ADC. Antigen recognition and binding were evidenced in ELISA studies with immobilized recombinant FAP and in flow cytometry analysis using FAP-expressing cell lines.
Antibody Activity Information 2					[1]
Half Maximal Effective Concentration (EC50)	0.33	nM	HT-1080 cells (FAP expression)	CVCL_0317
Antigen Expression	Positive FAP expression (FAP+++/++)
Antibody Function	Confirm the effect of the drug conjugation with the anti-FAP mAb and ADC on binding activity to cell line.
Antibody Antigen Binding Assay	The binding and internalization properties of OMTX705 were compared with naked OMTX005 anti-FAP antibody and an isotype/TAM558 control ADC. Antigen recognition and binding were evidenced in ELISA studies with immobilized recombinant FAP and in flow cytometry analysis using FAP-expressing cell lines.

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

OMTX-705 [Phase 1]

ADC Info

Discovered Using Patient-derived Xenograft Model

Click To Hide/Show 14 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 29.40% (Day 50)	High FAP expression (FAP+++)
Method Description	Activity of OMTX705 alone or combined with gemcitabine in the Panc 007 PDX model. Five-week-old Foxn1 nu/nu (nude) female mice were implanted subcutaneously with 23 mm 3 tumor pieces of Panc 007,a pancreatic cancer PDX model. OMTX705 was administered intraperitoneally (ip) 10 mg/kg once weekly.
In Vivo Model	Pancreatic cancer PDX model (PDX: Panc 007)
Experiment 2 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 34.50% (Day 30)	Moderate FAP expression (FAP++)
Method Description	Activity of OMTX705 alone or combined with gemcitabine in the TNBC PDX model Breast 014. OMTX705 was given intravenously (iv) 10 mg/kg once weekly for four doses (q7dx4).
In Vivo Model	Triple-negative breast cancer PDX model (PDX: Breast 014)
Experiment 3 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 40.70% (Day 30)	Moderate FAP expression (FAP++)
Method Description	Activity of OMTX705 alone or combined with gemcitabine in the TNBC PDX model Breast 014. OMTX705 in combination with PTX,OMTX705 intravenous (iv) 10 mg/kg once weekly for four doses (q7dx4). PTX intravenous (iv) 7.5 mg/kg once weekly for three doses (q7dx3) starting from week two.
In Vivo Model	Triple-negative breast cancer PDX model (PDX: Breast 014)
Experiment 4 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 49.30% (Day 37)	Moderate FAP expression (FAP++)
Method Description	Activity of OMTX705 alone or combined with gemcitabine in the Lung 024 PDX model. Five-week-old Foxn1 nu/nu (nude) female mice were implanted subcutaneously with 23 mm 3 tumor pieces of Panc 007,a pancreatic cancer PDX model. OMTX705 was administered intraperitoneally (ip) at 10 mg/kg,twice in the first week.
In Vivo Model	Lung cancer PDX model (PDX: Lung 024)
Experiment 5 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 57.50% (Day 37)	Moderate FAP expression (FAP++)
Method Description	Activity of OMTX705 alone or combined with gemcitabine in the Lung 024 PDX model. Lung adenocarcinoma Lung 024 PDX models treated with OMTX705 alone or combined with paclitaxel (PTX). OMTX705 and PTX were combined at a dose of 7.5 mg/kg of PTX administered intravenously once a week starting in the second week,and OMTX705 at a dose of 10 mg/kg administered by injection twice in the first week. Click to Show/Hide
In Vivo Model	Lung cancer PDX model (PDX: Lung 024)
Experiment 6 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 69.70% (Day 50)	High FAP expression (FAP+++)
Method Description	Activity of OMTX705 alone or combined with gemcitabine in the Panc 007 PDX model. Five-week-old Foxn1 nu/nu (nude) female mice were implanted subcutaneously with 23 mm 3 tumor pieces of Panc 007,a pancreatic cancer PDX model. OMTX705 was administered intraperitoneally (ip) 20 mg/kg once weekly.
In Vivo Model	Pancreatic cancer PDX model (PDX: Panc 007)
Experiment 7 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 71.60% (Day 37)	Moderate FAP expression (FAP++)
Method Description	Activity of OMTX705 alone or combined with gemcitabine in the Lung 024 PDX model. Lung adenocarcinoma Lung 024 PDX models treated with OMTX705 alone or combined with paclitaxel (PTX). OMTX705 was administered intraperitoneally (ip) at 30 mg/kg,once per week.
In Vivo Model	Lung cancer PDX model (PDX: Lung 024)
Experiment 8 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 74.00% (Day 33)	High FAP expression (FAP+++)
Method Description	OMTX705 exhibits potent effect in immunodeficient PDX models of different solid tumors. Five-week-old Foxn1 nu/nu (nude) female mice were implanted subcutaneously with 23 mm 3 tumor pieces of Panc 007,a pancreatic cancer PDX model. OMTX705 was given intravenously (iv) 20 mg/kg once weekly for four doses (q7dx4).
In Vivo Model	Pancreatic cancer PDX model (PDX: Panc 007)
Experiment 9 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 80.40% (Day 30)	Moderate FAP expression (FAP++)
Method Description	Activity of OMTX705 alone or combined with gemcitabine in the TNBC PDX model Breast 014. OMTX705 was given intravenously (iv) 30 mg/kg once weekly for four doses (q7dx4).
In Vivo Model	Triple-negative breast cancer PDX model (PDX: Breast 014)
Experiment 10 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 85.90% (Day 33)	High FAP expression (FAP+++)
Method Description	OMTX705 exhibits potent effect in immunodeficient PDX models of different solid tumors. Five-week-old Foxn1 nu/nu (nude) female mice were implanted subcutaneously with 23 mm 3 tumor pieces of Panc 007,a pancreatic cancer PDX model. OMTX705 was given intravenously (iv) 30 mg/kg once weekly for four doses (q7dx4).
In Vivo Model	Pancreatic cancer PDX model (PDX: Panc 007)
Experiment 11 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 85.90% (Day 33)	High FAP expression (FAP+++)
Method Description	OMTX705 exhibits potent effect in immunodeficient PDX models of different solid tumors. Five-week-old Foxn1 nu/nu (nude) female mice were implanted subcutaneously with 23 mm 3 tumor pieces of Panc 007,a pancreatic cancer PDX model. OMTX705 was given intravenously (iv) 40 mg/kg once weekly for four doses (q7dx4).
In Vivo Model	Pancreatic cancer PDX model (PDX: Panc 007)
Experiment 12 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 88.50% (Day 50)	High FAP expression (FAP+++)
Method Description	Activity of OMTX705 alone or combined with gemcitabine in the Panc 007 PDX model. Five-week-old Foxn1 nu/nu (nude) female mice were implanted subcutaneously with 23 mm 3 tumor pieces of Panc 007,a pancreatic cancer PDX model. OMTX705 was administered intraperitoneally (ip) 10 mg/kg once weekly,whereas gemcitabine was administered intraperitoneally 50 mg/kgweekly starting in the second week. Click to Show/Hide
In Vivo Model	Pancreatic cancer PDX model (PDX: Panc 007)
Experiment 13 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 91.10% (Day 33)	High FAP expression (FAP+++)
Method Description	OMTX705 exhibits potent effect in immunodeficient PDX models of different solid tumors. Five-week-old Foxn1 nu/nu (nude) female mice were implanted subcutaneously with 23 mm 3 tumor pieces of Panc 007,a pancreatic cancer PDX model. OMTX705 was given intravenously (iv) 50 mg/kg once weekly for four doses (q7dx4).
In Vivo Model	Pancreatic cancer PDX model (PDX: Panc 007)
Experiment 14 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 91.10% (Day 33)	High FAP expression (FAP+++)
Method Description	OMTX705 exhibits potent effect in immunodeficient PDX models of different solid tumors. Five-week-old Foxn1 nu/nu (nude) female mice were implanted subcutaneously with 23 mm 3 tumor pieces of Panc 007,a pancreatic cancer PDX model. OMTX705 was given intravenously (iv) 60 mg/kg once weekly for four doses (q7dx4).
In Vivo Model	Pancreatic cancer PDX model (PDX: Panc 007)

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	230.00 pM	High FAP expression (FAP+++)
Method Description	Cell viability in CAF07, HT1080-FAP, and HT1080-WT cells was analyzed via crystal violet staining after exposure to the indicated antibodies or free drug. Cells were treated for 120 hours with a serial dilution of antibodies (starting at 400 nmol/L) or free drugs (starting at 60 mol/L).
In Vitro Model	Fibrosarcoma	HT-1080 cells (FAP expression)		CVCL_0317
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	400.00 nM	Moderate FAP expression (FAP++)
Method Description	Cell viability in CAF07, HT1080-FAP, and HT1080-WT cells was analyzed via crystal violet staining after exposure to the indicated antibodies or free drug. Cells were treated for 120 hours with a serial dilution of antibodies (starting at 400 nmol/L) or free drugs (starting at 60 mol/L).
In Vitro Model	Normal	CAF cells		CVCL_R883

References

Ref 1	OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models. Clin Cancer Res. 2020 Jul 1;26(13):3420-3430.

Antibody Information

Citation

Visitor Map

Correspondence

Prof. Feng ZHU (zhufeng@zju.edu.cn)

Prof. Xiaowu DONG (dongxw@zju.edu.cn)

Prof. Luo FANG (fangluo@zjcc.org.cn)